Abstract
BackgroundThe efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer has been demonstrated in phase III trials. However, as patients receiving eribulin in daily practice do not necessarily meet all the eligibility criteria of clinical trials, data for such patients are limited.MethodsWe identified patients with locally advanced or metastatic breast cancer, treated with eribulin monotherapy between July 2011 and December 2015 at the National Cancer Center Hospital, Tokyo, Japan. Patients who would have met the following eligibility criteria from the EMBRACE trial were included in the eligible group, and the rest were included in the ineligible group: 1) Eastern Cooperative Oncology Group Performance status 0–2; 2) adequate function of principal organs; and 3) absence of active infection. We compared the relative dose intensity (RDI), tumor response, progression-free survival (PFS), overall survival (OS), and adverse events between the groups. Nominal and continuous values were compared using the Fisher’s exact test and Mann-Whitney U test, respectively. Survival outcomes were determined using Kaplan-Meier estimation, and between-group differences were assessed using the log-rank test.ResultsOf the 203 patients included, 34 were classified into the ineligible group and 169 into the eligible group. Initial dose reduction and treatment discontinuation due to adverse events (AEs) were more common in the ineligible group (initial dose reduction: 23.5% in the ineligible group vs. 7.7% in the eligible group, p = 0.011; treatment discontinuation due to AEs: 11.8% vs. 3.0%, p = 0.045). However, RDI (66% vs. 71%, p = 0.130), response rate (15.6% vs. 18.1%, p = 1.000), PFS (3.7 months vs. 4.0 months, p = 0.913), OS (11.5 months vs. 16.1 months, p = 0.743), AEs requiring hospitalization (5.9% vs. 6.5%, p = 1.000), and grade 3/4 AEs were similar in both groups. PFS, OS, AEs requiring hospitalization, and discontinuation due to AEs in the eligible group were comparable to those found in previous phase III trials.ConclusionThe safety and efficacy of eribulin monotherapy was demonstrated in a broader patient population than that eligible for clinical trials. Eribulin may be a treatment option in these patients with locally advanced or metastatic breast cancer, considering dose reduction and pre-existing dysfunctions.
Highlights
The efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer has been demonstrated in phase III trials
We considered that factors regarding prior chemotherapy do not affect the efficacy or safety of eribulin by themselves; we did not include them for the criteria for the classification
There was no significant difference in Response rate (RR) between the ineligible group and the eligible group (15.6%; 95% confidence interval [CI], 5.3–32.8% vs. 18.1%; 95% CI, 12.1– 25.3%; p = 1.000) or disease control rate (DCR) (65.6%; 95% CI, 46.8–81.4% vs. 62.5%; 95% CI, 54.1–70.4%; p = 0.841) (Additional file 2: Table S2)
Summary
We identified patients with locally advanced or metastatic breast cancer, treated with eribulin monotherapy between July 2011 and December 2015 at the National Cancer Center Hospital, Tokyo, Japan. Mm, platelets ≥10 × 104/mm, hemoglobin ≥10 g/dL, serum creatinine ≤2.0 mg/dL, total bilirubin ≤1.5 times the upper limit of normal [ULN], and aspartate transaminase [AST] and alanine transaminase [ALT] ≤ three times ULN, [AST and ALT ≤ five times ULN in patients with liver metastasis]); and 3) absence of active infection. Patients satisfying all these criteria were classified into the “eligible group”; patients not satisfying any one of these criteria were classified into the “ineligible group.”. Stable brain metastasis, and peripheral neuropathy were not included because they were not necessarily welldocumented at the initiation of eribulin
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
